- Company
- Will Piqray benefit be successful again?
- by Eo, Yun-Ho Feb 16, 2023 05:50am
- Attention is focusing on whether Piqray, a PIK3CA gene target anticancer drug, can succeed in re-challenge insurance benefits. According to related industries, Novartis Korea's breast cancer treatment Piqray is expected to be presented to the HIRA Cancer Disease Review Committee in March. The drug failed to pass the deliberation committee onc
- Company
- Astellas Korea appoints Junil Kim as new head
- by Eo, Yun-Ho Feb 15, 2023 05:59am
- Astellas Pharma Korea will now be run by a Korean head. According to industry sources, Junil Kim (50) was appointed to succeed Marker Weber and head the Korean subsidiary of Astellas Pharma. With the appointment, Astellas Korea will be welcoming the first Korean head in 7 years since the resignation of Jung Hae-doh in 2017. After Jung,
- Company
- Dementia with Lewy bodies rises as a new blue ocean
- by Feb 15, 2023 05:58am
- Dementia with Lewy bodies (DLB), the second most common type of neurodegenerative disease, is expected to rise as a blue ocean in the development of diagnostics and treatments for dementia. DLB has the limitation of being difficult to diagnose in the field as no clear diagnostic method has been developed for the disease. In the industry,
- Company
- GSK immuno-cancer drug Jemperli begins free supply in Korea
- by Eo, Yun-Ho Feb 14, 2023 05:49am
- GSK has launched a free supply program for the immuno-cancer drug Jemperli. According to related industries, GSK Korea is currently conducting Expanded Access Program (EAP) at 15 major medical institutions. Unlike the same type of immuno-cancer drug, Jemperli, a PD-1 inhibitor, plans to provide a first prescription opportunity to patients wh
- Company
- SK Plasma is exclusively selling Dacogen in Korea
- by Chon, Seung-Hyun Feb 14, 2023 05:48am
- SK Plasma announced on the 13th that it has signed an exclusive domestic sales contract with Janssen Korea for the treatment of myeloid dysplasia syndrome and acute myeloid leukemia. Under the agreement, SK Plasma will be in charge of the domestic distribution and marketing of Dakogen, while Janssen Korea will be in charge of producing and
- Company
- The Paradox of Shingrix
- by Moon, sung-ho Feb 14, 2023 05:48am
- Domestic companies such as GC Pharma are in trouble. Shingrix Expected to Change the Domestic Shingles Vaccine Market With Expensive Premium Vaccine. Analysts say that two months after its launch in Korea, it is rarely showing its strength in the hospital and clinic markets. In particular, at the clinical site, GlaxoSmithKline (GSK) seems to
- Company
- “5 of 10 TNF-αis prescribed last year were adalimumab”
- by Kim, Jin-Gu Feb 14, 2023 05:48am
- On the 13th, the healthcare big data analysis service Evidnet released the results of its analysis on the prescription data of 10 general hospitals nationwide last year. According to the results, ‘adalimumab (Humira)’ was the most frequently prescribed TNF- α inhibitor last year. Evidnet analyzed and announced 18,371 prescription data on
- Company
- Forxiga's patent war ended after eight years
- by Kim, Jin-Gu Feb 13, 2023 05:59am
- The Supreme Court sided with Generic in the dispute over Forxiga patents for SGLT-2 inhibitor-based diabetes treatment. Patent challengers will be able to release generics early after April 7. The Supreme Court's special second division ruled in the morning of the 2nd that AstraZeneca would dismiss the appeal in an appeal filed against 17 com
- Company
- Daewoong Nabota has obtained an item license in Singapore
- by Kim, Jin-Gu Feb 13, 2023 05:59am
- Daewoong Pharmaceutical announced on the 9th that its botulinum toxin "Nabota" obtained an item license in Singapore on the 20th of last month. The acquisition of Singapore permits was the first of its kind among domestic botulinum drugs, and Nabota has increased the number of licensed countries worldwide to 62. Nabota 100 units are approv
- Company
- Generic for Dukarb is coming soon
- by Kim, Jin-Gu Feb 13, 2023 05:58am
- According to the second trial decision of Dukarb on the 16th of this month, it is decided whether to release the core capacity at the same time. With Boryung Kanarb's generic set to be released next month, attention is focused on the second trial of the patent dispute, which is three days away. This is because the decision of the patent c
